Vor Biopharma logo

Vor Biopharma

VOR | NASDAQ
Chart Builder DCF Calculator
$18.97
-$0.45 (-2.32%)
At close: Nov 16, 2026, 4:00 PM ET
$18.83
-$0.14 (-0.74%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.32%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
30.3
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #789/1021 (Top 77%)

Key Statistics

Market Data

Market Cap $1.13B
1D Range
18.87 20.29
52W Range
6.86 25.10

Valuation (TTM)

PE 0.84
PB -8.25
EV/EBITDA 0.48

Valuation (NTM)

Forward PE N/A
Forward PEG -0.00
Price Target $33.50
Loading financial charts...

Profile

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product cand...

Sector Healthcare
Industry Biotechnology
Employees 76
IPO Date Feb 5, 2021
Fiscal Year January - December

Latest News

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

18 days ago · globenewswire.com

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study

25 days ago · reuters.com

Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

25 days ago · globenewswire.com

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Vor Bio To Participate in Upcoming September Conferences

3 months ago · globenewswire.com

Vor Bio To Participate in Upcoming September Conferences
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

4 months ago · globenewswire.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$33.50
Upside
+76.59%
Buy (2)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.